Literature DB >> 114638

Distribution of gold in blood following administration of auranofin (SK&F D-39162).

D T Walz, D E Griswold, M J DiMartino, E E Bumbier.   

Abstract

After oral administration of auranofin (SK&F D-39162), a new antiarthritic gold compound, to rats, dogs and humans, a major portion (approximately 50%) of the blood gold content was found to be associated with cellular components. This property is in marked contrast to that reported for gold sodium thiomalate and represents another of the many physical, chemical and pharmacological differences between these therapeutic gold compounds. Although the clinical significance of this property is not presently known, it is recommended that pharmacokinetic studies involving auranofin include the assessment of both blood and serum gold levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114638

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  7 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

2.  Gold nanoparticles: a revival in precious metal administration to patients.

Authors:  A S Thakor; J Jokerst; C Zavaleta; T F Massoud; S S Gambhir
Journal:  Nano Lett       Date:  2011-09-07       Impact factor: 11.189

Review 3.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  A comparison of the effects of two gold-containing therapeutic agents on articular chondrocyte growth in vitro.

Authors:  C J Kirkpatrick; W Mohr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

Review 5.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 6.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

7.  Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells.

Authors:  M J DiMartino; D T Walz
Journal:  Inflammation       Date:  1980-09       Impact factor: 4.092

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.